In a dramatic fall from grace, genetic testing company 23andMe filed for Chapter 11 bankruptcy protection on March 23, 2025, marking a stunning reversal for a firm once valued at $6 billion. The company that pioneered direct-to-consumer DNA testing now faces an uncertain future as it enters a court-supervised sale process amid mounting privacy concerns over its vast database of genetic information from more than 15 million customers. Financial Collapse and Leadership Turmoil 23andMe’s market capitalization has plummeted to approximately $14 million, a mere fraction of its peak valuation. The company has struggled to generate recurring revenue from its one-time … Continue reading 23andMe Bankruptcy: Genetic Data of 15M Users at Risk Amid Leadership Turmoil